

1132 U.S. PTO
03/04/02

CROWELL & MORING, L.L.P.
Intellectual Property Group
P.O. Box 14300
Washington, D.C. 20044-4300
(202) 624-2500

23911
PATENT TRADEMARK OFFICE

JC979 U.S. PTO
10/086623
03/04/02

March 4, 2002

Box PATENT APPLICATION

Commissioner for Patents
Washington, D.C. 20231

Re: New U.S. CIP Patent Appln.
Our Ref: 1064/44833C2

Sir:

Transmitted herewith for filing is a Continuation-In-Part application of pending U.S. Patent Application Serial No. 09/691,200, filed October 19, 2000, which is a Continuation-In-Part of U.S. Application No. 09/438,046, filed November 10, 1999 of:

Ulf ERIKSSON et al.

entitled: **PLATELET-DERIVED GROWTH FACTOR D, DNA CODING THEREFOR, AND USES THEREOF**

Enclosed are:

1. Specification, including 29 claims (pages 1-83).
2. 18 Sheets of drawings showing Figs. 1-25.
3. Application Data Sheet.
4. Sequence Listing and computer readable disk.

Benefit is hereby claimed under 35 U.S.C. §120 of pending U.S. patent application Serial No. 09/691,200, filed October 19, 2000, which is a continuation-in-part of U.S. Application No. 09/438,046, filed November 10, 1999 and claims the benefit of U.S. Provisional Application No. 60/107,852, filed November 10, 1998; U.S. Provisional Application No. 60/113,997, filed December 28, 1998; U.S. Provisional Application No. 60/150,604, filed August 26, 1999; U.S. Provisional Application No. 60/157,108, filed October 4, 1999; and U.S. Provisional Application No. 60/157,756, filed October 5, 1999.

10085633 030402

Basic Fee					\$370/740 = \$740.00
Total Claims	<u>29</u>	-	20	= <u>9</u>	x \$9/18 = \$162.00
Independent Claims	<u>8</u>	-	3	= <u>5</u>	x \$42/84 = \$420.00
Multiple Dependent Claim Presented					\$140/280 = \$
Total Filing Fee					<u>\$1322.00</u>

Respectfully submitted,



J.D. Evans
Reg. No. 26,269
Kening Li, Ph.D.
Registration No. 44,872

JDE:KL:tlm
(CAM #: 29065.003)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: ULF ERIKSSON
Serial No.: TO BE ASSIGNED
Filed: March 4, 2002
Title: PLATELET-DERIVED GROWTH FACTOR D, DNA CODING
THEREFOR, AND USES THEREOF

STATEMENT UNDER 37 C.F.R. §1.821(f)


Box Sequence
Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the requirements under 37 C.F.R. §1.821(f), the undersigned hereby states that the substitute sequence listing information recorded on the accompanying computer readable form is identical to the submitted written copy of the substitute sequence listing.

Respectfully submitted,

March 4, 2002



J. D. Evans
Registration No. 26,269
Kening Li, Ph.D.
Registration No. 44,872

CROWELL & MORING, LLP
Intellectual Property Group
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 624-2500
Facsimile No.: (202) 628-8844
JDE:KL:tlm
(CAM #: 29065.003)